

Supplemental material

Table 1: Eligible VHA Clinics from which post-discharge BP measurements were used for follow-up

Coumadin clinic

Diabetes, Endocrine/ metabolism

General internal medicine; Primary care/medicine; Women's Clinic

Geriatrics clinic; Geriatric evaluation and Management; Geriatric primary care

Hypertension; High Blood pressure clinic

Cardiology

Infectious disease

Mental health primary care

Renal/ Nephrology

Pulmonary Medicine/ chest clinic

Neurology

Table 2: Comparison of patients included in sample of post discharge BP control (n=2054) to those excluded because of no outpatient visit or no post discharge BP measure (n=1105)

	<i>Post DC Sample</i> <i>N=2054</i>	<i>Missing Post DC BP</i> <i>N=1105</i>	<i>p-value</i>
Gender			
Males	2000(97.4)	1082(97.9)	0.3412
Females	54(2.6)	23(2.1)	
Age			
<65	1040(50.6)	462(41.8)	<.0001
65- 74	449(21.8)	256(23.2)	
75+	565(27.6)	387(35.0)	
Race			
White	1265(66.0)	691(68.3)	0.2565
Black	500(26.2)	256(25.3)	
Other	150(7.8)	64(6.3)	
Missing race	139	94	
NIH stroke scale			
0-2	1152(56.0)	483(43.7)	<.0001
3-9	808(39.4)	459(41.5)	
10 +	94(4.6)	163(14.8)	
Weight (mean ±SD)	193.75 ± 44.17	183.56 ± 41.70	<.0001
Current Smoker (%)	752(36.6)	387(35.0)	0.3751
Charlson Score (mean ±SD)	4.5 ± 1.9	4.8 ± 2.0	<.0001
Number of Co morbidities at admission (mean ±SD)	3.5 ± 2.0	3.4 ± 2.1	0.1249
Co morbidities (%)			
Cerebrovascular disease *	552(26.8)	352(31.9)	0.0031
Cardiovascular disease †	723(35.2)	404(36.6)	0.4462
Atrial Fibrillation	290(14.2)	181(16.4)	0.0888
Diabetes	866(42.2)	399(36.1)	0.0009
Hyperlipidemia	1091(53.2)	438(39.6)	<.0001
Renal disease	22(1.0)	8(0.7)	0.3374
Liver disease	46(2.2)	12(1.1)	0.0213

HIV	14(0.6)	7(0.6)	0.8739
Cancer ‡	130(6.4)	86(7.8)	0.1226
Pulmonary disease	312(15.2)	166(15.0)	0.9004
Use of antipsychotic medication	102(5.0)	55(5.0)	0.9887
Depression	358(17.4)	158(14.3)	0.0232
Dementia	106(5.2)	119(10.8)	<.0001
Peptic Ulcer disease	36(1.8)	18(1.6)	0.7981
Rheumatologic Disorders§	8(0.4)	8(0.7)	0.2066
N medications at admission (mean ±SD)	7.4 ± 4.9	6.2 ± 4.7	<.0001
Discharged disposition (%)			<.0001
Home	1637(79.6)	592(53.6)	
Nursing Facility	183 (8.9)	259 (23.4)	
Transfer to short term hospital	19 (0.9)	26 (2.4)	
Federal Health Care Facility	90 (4.4)	113 (10.2)	
Intermediate Care Facility	30 (1.5)	51 (4.6)	
Other Health Care Institution	20 (1.0)	8 (0.7)	
Inpatient rehabilitation	72 (3.5)	50 (4.5)	
Medicare long term care	2 (0.1)	4 (0.4)	
Psychiatric Hospital	0 (0.0)	1 (0.1)	
Critical Access Hospital	1 (0.0)	1 (0.1)	

*Cerebrovascular disease includes carotid endarterectomy, carotid stent, ischemic stroke or TIA

† Cardiovascular disease includes history of coronary artery disease, acute myocardial infarction, coronary artery bypass, percutaneous transluminal coronary angioplasty with or without stent placement or any history of peripheral vascular disease

‡ Cancer includes any diagnosis of leukemia, lymphoma, or any solid tumor in past 5 years, metastatic tumor, or multiple myeloma

|| Antipsychotics include chlorpromazine; fluphenazine; thioridazine; trifluoroperazine; thiothixene; aripiprazole; clozapine; haloperidol; loxapine; molindone; olanzapine; quetiapine; risperidone; ziprasidone

§ Rheumatologic disorders include Lupus and any vasculitis

Table 3: Subgroup Analysis--Odds of BP control at discharge follow up visit among the sample of patients with uncontrolled BP at hospital discharge (n=885 in 123 VAMCs)

	<i>BP uncontrolled</i> <i>N=360</i>	<i>BP controlled</i> <i>N=525</i>	<i>Unadjusted OR</i> <i>(95% CI)</i>	<i>Adjusted OR†</i> <i>(95%CI)</i>
Gender				
Male	97.6	97.3	Ref	Ref
Female	2.6	2.7	1.07 (0.45, 2.52)	0.99 (0.38, 2.56)
Age	53.0	46.7	Ref	Ref
<65				
65-74	23.4	23.4	1.14 (0.81, 1.60)	1.11 (0.76, 1.62)
75+	23.6	29.9	1.44 (1.04, 2.00)	1.07 (0.72, 1.59)
Race*				
White	55.0	67.0	Ref	Ref
Black	34.8	27.2	0.64 (0.47, 0.88)	0.80 (0.56, 1.14)
Other	10.2	5.8	0.46 (0.27, 0.79)	0.49 (0.28, 0.86)
N co-morbidities at admission (mean± SD)	3.4 ± 1.9	3.6 ± 2.0	1.04 (0.97, 1.12)	1.16 (1.00, 1.34)
Co-morbidities				
Cerebrovascular disease	24.4	31.4	1.42 (1.04, 1.92)	1.25 (0.85, 1.83)
CVD	33.0	33.5	1.02 (0.77, 1.36)	0.78 (0.51, 1.21)
Diabetes	50.8	42.1	0.70 (0.54, 0.92)	0.68 (0.47, 0.96)
Hypertension	90.2	84.4	0.58 (0.38, 0.89)	0.56 (0.34, 0.93)
Hyperlipidemia	50.8	53.5	1.11 (0.85, 1.46)	0.94 (0.66, 1.33)
Systolic BP at Discharge mmHg (mean± SD)	157.0 ± 15.6	152.4 ± 12.8	0.98 (0.97, 0.99)	0.98 (0.97, 0.99)
Diastolic BP at Discharge mmHg (mean± SD)	86.5 ± 12.6	82.5 ± 12.1	0.97 (0.96, 0.98)	0.98 (0.96, 0.99)
N Visits Post Discharge (mean± SD)	5.8 ± 4.6	6.0 ± 4.6	1.01 (0.98, 1.04)	1.01 (0.98, 1.04)
Antihypertensives at DC				
Thiazide + ACE/ ARB	21.2	21.0	0.99 (0.71, 1.38)	1.22 (0.79, 1.89)
Thiazide	6.4	6.5	1.01 (0.58, 1.76)	1.10 (0.57, 2.11)
ACE/ARB	41.4	40.6	0.97 (0.73, 1.27)	1.03 (0.72, 1.48)
Beta Blockers	55.2	48.0	0.75 (0.57, 0.98)	0.80 (0.58, 1.11)

CCB	37.8	32.2	0.78 (0.59, 1.04)	0.85 (0.62, 1.18)
All other classes	35.6	31.4	0.83 (0.62, 1.11)	0.79 (0.57, 1.09)

* Missing race: BP uncontrolled N= 29 (8.1%); BP controlled N=43 (8.2%)

† Adjusted model (n=813) includes gender, age, race, history of CVD, cerebrovascular disease, Diabetes, Hypertension, Hyperlipidemia, number of co- morbidities at admission, Systolic and Diastolic BP at Discharge, number of visits since hospital discharge, Class of antihypertensive drugs prescribed at discharge with facility as a random effect (N=121)